Research
Hormonal
GLP-1 receptor agonists enhance insulin secretion, support weight loss, and exhibit neuroprotective and cardiovascular benefits.
Practitioners can consider GLP-1 receptor agonists for their multifaceted benefits in diabetes management.
StrongSupportsmedium confidence
GLP-1 receptor agonists enhance insulin secretion, support weight loss, and exhibit neuroprotective and cardiovascular benefits.
Why this rating
The review summarizes findings from multiple studies.
Source
A comprehensive review of the multisystem benefits of antidiabetic drugs in aging beyond glycemic control
Fatema Tuz Zohora et al. · Translational Medicine of Aging · 2025
DOI 10.1016/j.tma.2025.08.005
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →